MW-151 treatment prevented loss of synapses, as measured by western blots for the levels of PSD-95, synaptophysin, syntaxin, and synaptosomal-associated protein 25 (SNAP25), without affecting amyloid plaque load or soluble Aβ concentrations. This evidence concerns the gene SNAP25 and amyloidosis.